News
31.10.19
By Sterling Pharma Solutions

Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions, has launched a Technology and Innovation Programme designed to allow the company and its partners to explore the commercial viability and practical application of new technologies in the pharmaceutical industry.

In addition to Sterling’s existing projects with a number of universities in the UK, the programme will also see the company form new global partnerships with other academic institutes and technology companies in order to explore new technologies and develop innovative solutions to API development and manufacturing challenges.

The programme will support the work that Sterling already does in hazard evaluation and process design, hazardous and chiral chemistry and continuous processing, as well as bolster the activity at its biological waste-water treatment facility in the UK.

Mark Muldowney, head of technology and innovation, at Sterling Pharma Solutions said: “We’re delighted to announce the launch of our technology and innovation programme. The programme reinforces our dedication to exploring new technologies and working together with academic institutes  to assess their commercial viability.

“We recognise the importance of continuously improving our operational performance and building our API capabilities, particularly as new, more complex molecules enter the drug pipeline.

“Over the last few years we have invested heavily in our capabilities, including a £6m investment into our milling and micronisation facility in 2018 which is due to open in 2020 and several commercial laboratory flow systems for the benefit of customer projects.

“This programme will allow us to continue to commit time and resource to finding innovative solutions that benefit the pharmaceutical API development and manufacturing process.”

Key areas the programme will focus on include bio-catalysis, flow chemistry, chiral chemistry, fluorinations and hazardous chemistry techniques including the use of diazomethane (DAM).

As part of the programme, Sterling is already working closely with professors at Durham University, UK on a fluorination project and Oxford University on a chiral chemistry project, among others. In addition, the CDMO also has a number of customer projects underway that utilise flow and DAM technology.

Sterling Pharma Solutions, which has sites in the UK and the US, is a well-established developer and manufacturer of pharmaceutical APIs. Specialising in hazardous chemistry and handling controlled substances, the company is dedicated to continuously developing innovative solutions to customer challenges, such as handling potent molecules and increasing operational effectiveness.